TCGA-A2-A1FW-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 18
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.450
- PROTEIN_SECRETION+0.410
- E2F_TARGETS+0.370
- MITOTIC_SPINDLE+0.300
- ANDROGEN_RESPONSE+0.250
- MYC_TARGETS_V1+0.200
- UV_RESPONSE_DN+0.200
- CHOLESTEROL_HOMEOSTASIS+0.150
- PI3K_AKT_MTOR_SIGNALING+0.140
- TGF_BETA_SIGNALING+0.140
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- ALLOGRAFT_REJECTION-0.420
- ANGIOGENESIS-0.420
- IL6_JAK_STAT3_SIGNALING-0.420
- TNFA_SIGNALING_VIA_NFKB-0.370
- COAGULATION-0.350
- INFLAMMATORY_RESPONSE-0.330
- NOTCH_SIGNALING-0.330
- KRAS_SIGNALING_UP-0.270
- APICAL_JUNCTION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR3147748 | — | — | 0.862 |
| 2 | MDT-AP-3021 | Med | Medulloblastoma | 0.862 |
| 3 | 8ca13509-abad-46b7-92f4-fa741bc52b42 | — | — | 0.861 |
| 4 | MDT-AP-3205 | Med | Medulloblastoma | 0.856 |
| 5 | MNG1204 | — | — | 0.856 |
| 6 | MDT-AP-3288 | Med | Medulloblastoma | 0.849 |
| 7 | SRR12202425 | — | — | 0.849 |
| 8 | SRR1797285 | — | cohortSC | 0.847 |
| 9 | R144 | — | — | 0.846 |
| 10 | MDT-AP-3402 | Med | Medulloblastoma | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |